Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
MiniMed Group, Inc.
Market Cap
$560.00M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$554.85M
Return on Equity (ROE)
-306.61%
TTM Avg
-169.61%
3Y Avg
-163.97%
5Y Avg
-73.13%
Market Cap
$552.89M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$554.29M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$566.81M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$569.16M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$574.01M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$542.85M
Return on Equity (ROE)
N/A
TTM Avg
91.17%
3Y Avg
180.92%
5Y Avg
76.31%
Market Cap
$541.30M
Return on Equity (ROE)
0.44%
TTM Avg
-17.98%
3Y Avg
71.24%
5Y Avg
-6.51%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $554.85M | -306.61% | -169.61% | -163.97% | -73.13% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $552.89M | -60.79% | -73.94% | -62.04% | -71.62% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $554.29M | N/A | 44.05% | 44.05% | 44.05% |
| CorMedix Inc. (CRMD)vs › | $566.81M | 40.62% | 9.52% | -25.24% | -32.61% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $569.16M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $574.01M | N/A | 161.13% | 93.89% | 96.07% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.85M | N/A | 91.17% | 180.92% | 76.31% |
| Delcath Systems, Inc. (DCTH)vs › | $541.30M | 0.44% | -17.98% | 71.24% | -6.51% |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | 6.49% | 6.51% | -75.00% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
